Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 6/2013

01-12-2013 | Office Urology (N Shore, Section Editor)

Understanding Clinic Options for Overactive Bladder

Authors: Jamie M. Bartley, Emily S. Blum, Larry T. Sirls, Kenneth M. Peters

Published in: Current Urology Reports | Issue 6/2013

Login to get access

Abstract

Overactive bladder (OAB) is a symptom complex of urinary frequency, nocturia and urgency with or without urgency incontinence that adversely impacts patient’s quality of life. Conservative management begins in the outpatient clinic, often with significant improvement and patient satisfaction. In this review we will discuss the evaluation of OAB and review treatment options focusing on behavioral modification, medical therapy, and neuromodulation. These treatment options are offered in a stepwise fashion, remembering that more than one may be needed and can be used concomitantly.
Literature
1.
Haylen BT et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5–26.PubMedCrossRef
2.
Coyne KS et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77:1081–7.PubMedCrossRef
3.
Milsom I, Abrams P, Cardozo L, Roberts RG, Thuè Roff§ J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–6.PubMedCrossRef
4.
Irwin DE et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–14. discussion 1314–5.PubMedCrossRef
5.
Stewart WF et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36.PubMed
6.
Coyne KS et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB-POLL. Neurourol Urodyn. 2013;32:230–7.PubMedCrossRef
7.
Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108:1132–8.PubMedCrossRef
8.
Irwin DE et al. The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 2009;103:202–9.PubMedCrossRef
9.
Coyne KS et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388–95.PubMedCrossRef
10.
Sexton CC et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15:S98–107.PubMed
11.
Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol. 2002;136:641–3.PubMedCrossRef
12.
de Groat WC. A neurologic basis for the overactive bladder. Urology. 1997;50:36–52. discussion 53–6.PubMedCrossRef
13.
Brading AF. A myogenic basis for the overactive bladder. Urology. 1997;50:57–67. discussion 68–73.PubMedCrossRef
14.
Meng E, Wei-Yu L, Wei-Chia L, Yao-Chi C. Pathophysiology of Overactive Bladder. Low Urin Tract Symptoms. 2012;4(s1):48–55.
15.
Uzun H, Zorba OU. Metabolic syndrome in female patients with overactive bladder. Urology. 2012;79:72–5.PubMedCrossRef
16.
Banakhar MA, Al-Shaiji TF, Hassouna MM. Pathophysiology of overactive bladder. Int Urogynecol J. 2012;23:975–82.PubMedCrossRef
17.
Lee UJ et al. Defining and managing overactive bladder: disagreement among the experts. Urology. 2013;81:257–62.PubMedCrossRef
18.
•• Gormley EA, et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline. J Urol (2012). This article presents a comprehensive review and treatment recommendations for OAB as determined by the American Urologic Association and the Society for Urodynamics and Female Urology. Of note, Botox for idiopathic OAB and the beta-3 agonist were not available outside of research studies prior to the publication of these recommendations.
19.
Davis NJ, et al. Caffeine Intake and its Association with Urinary Incontinence in United States Men: Results from National Health and Nutrition Examination Surveys 2005–2006 and 2007–2008. J Urol (2012).
20.
Gleason JL et al. Caffeine and urinary incontinence in US women. Int Urogynecol J. 2013;24:295–302.PubMedCrossRef
21.
Jo JK et al. Analysis of the risk factors for overactive bladder on the basis of a survey in the community. Korean J Urol. 2012;53:541–6.PubMedCrossRef
22.
Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306:737–45.PubMedCrossRef
23.
Burgio KL et al. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. J Am Geriatr Soc. 2011;59:2209–16.PubMedCrossRef
24.
Kershen R, Mann-Gow T, Yared J, Stromberg I, Zvara P. Caffeine ingestion causes detrusor overactivity and afferent nerve excitation in mice. J Urol. 2012;188:1986–92.PubMedCrossRef
25.
Lohsiriwat S, Hirunsai M, Chaiyaprasithi B. Effect of caffeine on bladder function in patients with overactive bladder symptoms. Urol Ann. 2011;3:14–8.PubMedCrossRef
26.
Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int. 2008;102:62–6.PubMedCrossRef
27.
Zimmern P, Litman HJ, Mueller E, Norton P, Goode P. Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women. BJU Int. 2010;105:1680–5.PubMedCrossRef
28.
Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol. 2011;8:483–94.PubMedCrossRef
29.
Subak LL et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360:481–90.PubMedCrossRef
30.
Godec CJ. "Timed voiding"–a useful tool in the treatment of urinary incontinence. Urology. 1984;23:97–100.PubMedCrossRef
31.
Burgio KL et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA. 2002;288:2293–9.PubMedCrossRef
32.
Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology. 2004;63:61–6.PubMedCrossRef
33.
Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2012;12, CD003193.PubMed
34.
Burgio KL et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med. 2008;149:161–9.PubMedCrossRef
35.
Klutke CG et al. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication. J Urol. 2009;181:2599–607.PubMedCrossRef
36.
Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor–which is the main mechanism of action? Eur Urol. 2003;43:1–5.PubMedCrossRef
37.
Novara G et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54:740–63.PubMedCrossRef
38.
Oefelein MG. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf. 2011;34:733–54.PubMedCrossRef
39.
Benner JS et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105:1276–82.PubMedCrossRef
40.
Peeker R, Samsioe G, Kowalski J, Andersson AS, Bergqvist A. A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden. Scand J Urol Nephrol. 2010;44:138–46.PubMedCrossRef
41.
Sears CL, Lewis C, Noel K, Albright TS, Fischer JR. Overactive bladder medication adherence when medication is free to patients. J Urol. 2010;183:1077–81.PubMedCrossRef
42.
Igawa Y, Aizawa N, Homma Y. Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol. 2010;51:811–8.PubMedCrossRef
43.
Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147 Suppl 2:S88–119.PubMedCrossRef
44.
Chapple CR, et al. A proof-of-concept study: Mirabegron, a new therapy for overactive bladder. Neurourol Urodyn (2013)
45.
Tyagi P, Tyagi V, Chancellor M. Mirabegron: a safety review. Expert Opin Drug Saf. 2011;10:287–94.PubMedCrossRef
46.
•• Chapple, C.R. et al. Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a beta(3)-Adrenoceptor Agonist, in Overactive Bladder. Eur Urol (2012). This article presents data from a phase 3 trial supporting the efficacy and safety of the first in a new class of medications for treating OAB. Dry mouth, one of the most common sides effects of anticholinergics was 3 times less likely in the miregebron group.
47.
Otsuki H et al. beta3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol. 2013;45:53–60.PubMedCrossRef
48.
Lee J et al. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults. Clin Ther. 2013;35:333–41.PubMedCrossRef
49.
van Kerrebroeck PE et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178:2029–34.PubMedCrossRef
50.
Sutherland SE et al. Sacral nerve stimulation for voiding dysfunction: One institution's 11-year experience. Neurourol Urodyn. 2007;26:19–28. discussion 36.PubMedCrossRef
51.
• Al-zahrani AA, Elzayat EA, Gajewski JB. Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. J Urol. 2011;185:981–6. This study presents data on the success of SNS with a median follow up of 50.7 months, one of the longest in the literature. 85% of patietns with OAB were still reporting successful treatment. 39% of patients did need reoperation/revision of their device, most commonly for loss of stimulation.PubMedCrossRef
52.
Groen J, Blok BF, Bosch JL. Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. J Urol. 2011;186:954–9.PubMedCrossRef
53.
Carey M, Fynes M, Murray C, Maher C. Sacral nerve root stimulation for lower urinary tract dysfunction: overcoming the problem of lead migration. BJU Int. 2001;87:15–8.PubMedCrossRef
54.
Everaert K et al. A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation. Eur Urol. 2004;45:649–54.PubMedCrossRef
55.
Leong RK, De Wachter SG, Nieman FH, de Bie RA, van Kerrebroeck PE. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy. Neurourol Urodyn. 2011;30:1249–52.PubMed
56.
Borawski KM, Foster RT, Webster GD, Amundsen CL. Predicting implantation with a neuromodulator using two different test stimulation techniques: A prospective randomized study in urge incontinent women. Neurourol Urodyn. 2007;26:14–8.PubMedCrossRef
57.
• Staskin DR, Peters KM, MacDiarmid S, Shore N, de Groat WC. Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep. 2012;13:327–34. This article discusses the costs of a variety of OAB treatments including medications, neuromodulation (PTNS and SNS), Botox and augmentation cystoplasty.PubMedCrossRef
58.
Peters KM et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. Neurourol Urodyn. 2013;32:24–9.PubMedCrossRef
59.
•• Peters KM et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438–43. This article is the only sham controlled study that has been done in the field of neuromodulation. Results show a significant improvement in patient symptoms on a variety of parameters and support the use of PTNS in the treatment of OAB.PubMedCrossRef
60.
Peters KM et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182:1055–61.PubMedCrossRef
61.
Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, Macdiarmid SA. Percutaneous Tibial Nerve Stimulation for the Long-Term Treatment of Overactive Bladder: 3-Year Results of the STEP Study. J Urol (2012).
62.
Finazzi-Agro E et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184:2001–6.PubMedCrossRef
63.
Yoong W, Shah P, Dadswell R, Green L. Sustained effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome: 2-year follow-up of positive responders. Int Urogynecol J (2012).
64.
Tai C et al. Prolonged poststimulation inhibition of bladder activity induced by tibial nerve stimulation in cats. Am J Physiol Renal Physiol. 2011;300:F385–92.PubMedCrossRef
65.
Peters KM, et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. Neurourol Urodyn (2012).
66.
Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, Macdiarmid SA. Percutaneous Tibial Nerve Stimulation (PTNS) for the Long-Term Treatment of Overactive Bladder: Three-Year Results of the STEP Study. J Urol (2012).
67.
Coelho A et al. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol. 2010;57:884–90.PubMedCrossRef
68.
•• Nitti VW, et al. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. J Urol (2012). This study shows the benefit of Botox vs. placebo in patients with OAB that failed medical therapy with anticholinergics. Patients reported statistically significant improvement in all overactive bladder symptoms and health related quality of life scales. These results lead to FDA approval of Botox for treatment of idiopathic OAB.
69.
Visco AG et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012;367:1803–13.PubMedCrossRef
70.
Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111:106–13.PubMedCrossRef
71.
Peters KM, Feber KM, Bennett RC. Sacral versus pudendal nerve stimulation for voiding dysfunction: a prospective, single-blinded, randomized, crossover trial. Neurourol Urodyn. 2005;24:643–7.PubMedCrossRef
72.
Peters KM, Killinger KA, Boguslawski BM, Boura JA. Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn. 2010;29:1267–71.PubMedCrossRef
73.
Janssen DA, Farag F, Heesakkers JP. Urgent-SQ implant in treatment of overactive bladder syndrome: 9-year follow-up study. Neurourol Urodyn (2012).
Metadata
Title
Understanding Clinic Options for Overactive Bladder
Authors
Jamie M. Bartley
Emily S. Blum
Larry T. Sirls
Kenneth M. Peters
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Urology Reports / Issue 6/2013
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-013-0353-6

Other articles of this Issue 6/2013

Current Urology Reports 6/2013 Go to the issue

Benign Prostatic Hyperplasia (K McVary and S Kaplan, Section Editors)

Mirabegron for Male Lower Urinary Tract Symptoms

Benign Prostatic Hyperplasia (K McVary and S Kaplan, Section Editors)

The Evaluation and Treatment of Prostate-Related LUTS in the Primary Care Setting: The Next STEP

Benign Prostatic Hyperplasia (K McVary and S Kaplan, Section Editors)

Which Laser Works Best for Benign Prostatic Hyperplasia?

Office Urology (N Shore, Section Editor)

The Evaluation and Management of Testosterone Deficiency: the New Frontier in Urology and Men’s Health

Benign Prostatic Hyperplasia (K McVary and S Kaplan, Section Editors)

Urethral Lift for Benign Prostatic Hyperplasia: A Comprehensive Review of the Literature

Office Urology (N Shore, Section Editor)

Update on the Evaluation of Repeated Stone Formers